256 related articles for article (PubMed ID: 18042473)
1. Cardiac safety profile of nebulized formoterol in adults with COPD: a 12-week, multicenter, randomized, double- blind, double-dummy, placebo- and active-controlled trial.
Nelson HS; Gross NJ; Levine B; Kerwin EM; Rinehart M; Denis-Mize K;
Clin Ther; 2007 Oct; 29(10):2167-78. PubMed ID: 18042473
[TBL] [Abstract][Full Text] [Related]
2. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
[TBL] [Abstract][Full Text] [Related]
3. Long-term safety of nebulized formoterol: results of a twelve-month open-label clinical trial.
Donohue JF; Hanania NA; Fogarty C; Campbell SC; Rinehart M; Denis-Mize K
Ther Adv Respir Dis; 2008 Aug; 2(4):199-208. PubMed ID: 19124372
[TBL] [Abstract][Full Text] [Related]
4. Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial.
Tashkin DP; Littner M; Andrews CP; Tomlinson L; Rinehart M; Denis-Mize K
Respir Med; 2008 Apr; 102(4):479-87. PubMed ID: 18258423
[TBL] [Abstract][Full Text] [Related]
5. Nebulized formoterol provides added benefits to tiotropium treatment in chronic obstructive pulmonary disease.
Tashkin DP; Hanania NA; McGinty J; Denis-Mize K; Chaudry I
Adv Ther; 2009 Nov; 26(11):1024-34. PubMed ID: 19953349
[TBL] [Abstract][Full Text] [Related]
6. Cardiac safety of formoterol 12 microg twice daily in patients with chronic obstructive pulmonary disease.
Campbell SC; Criner GJ; Levine BE; Simon SJ; Smith JS; Orevillo CJ; Ziehmer BA
Pulm Pharmacol Ther; 2007; 20(5):571-9. PubMed ID: 16911869
[TBL] [Abstract][Full Text] [Related]
7. Nebulized formoterol fumarate: Dose selection and pharmacokinetics.
Gross NJ; Kerwin E; Levine B; Kim KT; Denis-Mize K; Hamzavi M; Carpenter M; Rinehart M
Pulm Pharmacol Ther; 2008 Oct; 21(5):818-23. PubMed ID: 18655841
[TBL] [Abstract][Full Text] [Related]
8. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, tolerability, and effect on asthma-related quality of life of formoterol bid via multidose dry powder inhaler and albuterol QID via metered dose inhaler in patients with persistent asthma: a multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group study.
Busse W; Levine B; Andriano K; Lavecchia C; Yegen U
Clin Ther; 2004 Oct; 26(10):1587-98. PubMed ID: 15598475
[TBL] [Abstract][Full Text] [Related]
10. Safety, tolerability and efficacy of indacaterol, a novel once-daily beta(2)-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial.
Beier J; Chanez P; Martinot JB; Schreurs AJ; Tkácová R; Bao W; Jack D; Higgins M
Pulm Pharmacol Ther; 2007; 20(6):740-9. PubMed ID: 17088091
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the efficacy and safety of arformoterol 15 microg twice daily and arformoterol 30 microg once daily in COPD: a single-dose, multicenter, randomized, modified-blind, two-way crossover study.
Panettieri RA; MacIntyre N; Sims M; Kerwin E; Fogarty C; Noonan M; Claus R; Andrews WT
Clin Ther; 2009 Aug; 31(8):1716-23. PubMed ID: 19808130
[TBL] [Abstract][Full Text] [Related]
12. Safety and tolerability of high-dose formoterol (via Aerolizer) and salbutamol in patients with chronic obstructive pulmonary disease.
Rosenkranz B; Rouzier R; Kruse M; Dobson C; Ayre G; Horowitz A; Fitoussi S
Respir Med; 2006 Apr; 100(4):666-72. PubMed ID: 16303295
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of formoterol fumarate delivered by nebulization to COPD patients.
Gross NJ; Nelson HS; Lapidus RJ; Dunn L; Lynn L; Rinehart M; Denis-Mize K;
Respir Med; 2008 Feb; 102(2):189-97. PubMed ID: 18363201
[TBL] [Abstract][Full Text] [Related]
14. Long-term safety and efficacy of formoterol fumarate inhalation solution in patients with moderate-to-severe COPD.
Hanania NA; Sethi S; Koltun A; Ward JK; Spanton J; Ng D
Int J Chron Obstruct Pulmon Dis; 2019; 14():117-127. PubMed ID: 30643398
[TBL] [Abstract][Full Text] [Related]
15. Arrhythmias in patients with chronic obstructive pulmonary disease (COPD): occurrence frequency and the effect of treatment with the inhaled long-acting beta2-agonists arformoterol and salmeterol.
Hanrahan JP; Grogan DR; Baumgartner RA; Wilson A; Cheng H; Zimetbaum PJ; Morganroth J
Medicine (Baltimore); 2008 Nov; 87(6):319-328. PubMed ID: 19011503
[TBL] [Abstract][Full Text] [Related]
16. The pulmonary and extra-pulmonary effects of high-dose formoterol in COPD: a comparison with salbutamol.
Goldkorn A; Diotto P; Burgess C; Weatherall M; Holt S; Beasley R; Siebers R
Respirology; 2004 Mar; 9(1):102-8. PubMed ID: 14982610
[TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind, double-dummy, safety crossover trial comparing cumulative doses up to 96 microg of formoterol delivered via an HFA-134a-propelled pMDI vs. same cumulative doses of formoterol DPI and placebo in asthmatic patients.
Molimard M; Guenolé E; Duvauchelle T; Vicaut E; Lefrançois G
Respiration; 2005; 72 Suppl 1():28-34. PubMed ID: 15915010
[TBL] [Abstract][Full Text] [Related]
18. The CONCEPT trial: a 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma.
FitzGerald JM; Boulet LP; Follows RM
Clin Ther; 2005 Apr; 27(4):393-406. PubMed ID: 15922813
[TBL] [Abstract][Full Text] [Related]
19. Formoterol for maintenance and as-needed treatment of chronic obstructive pulmonary disease.
Campbell M; Eliraz A; Johansson G; Tornling G; Nihlén U; Bengtsson T; Rabe KF
Respir Med; 2005 Dec; 99(12):1511-20. PubMed ID: 16199148
[TBL] [Abstract][Full Text] [Related]
20. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study.
Sharafkhaneh A; Southard JG; Goldman M; Uryniak T; Martin UJ
Respir Med; 2012 Feb; 106(2):257-68. PubMed ID: 22033040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
